Clinical Trial: A Randomized, Controlled, Open-label, Multicenter Phase II Study of Rellafup-α Plus Systemic Chemotherapy With or Without Intraperitoneal Chemotherapy as First-line Treatment for HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis (China)

China, Sept. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Randomized, Controlled, Open-label, Multicenter Phase II Study of Rellafup-α Plus Systemic Chemotherapy With or Without Intraperitoneal Chemotherapy as First-line Treatment for HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133373

Registration Time: 2026/09/24

Type: Interventional study

Primary Sponsor: The first hospital of China medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343217

Published by HT Digital Content Services with permiss...